SLC5A2 and Hypoglycemia: Recently developed drugs, such as dipeptidyl peptidase-4 (DPP4) and sodium-glucose co-transporter-2 (SGLT2) inhibitors, are expected to have cardiovascular benefits owing to the low risk of hypoglycemia and weight gain [6,7].